Scarica l'app Stockscreener
1.63
9.44%
-0.17
Pre-mercato:
1.66
0.03
+1.84%
Rezolute Inc Borsa (RZLT) Ultime notizie
Rezolute CFO Evans buys shares worth $79,577 By Investing.com - Investing.com Canada
Elam Nevan C, Rezolute CEO, buys $50k in RZLT shares By Investing.com - Investing.com Canada
Daron Evans Buys 40,000 Shares of Rezolute (NASDAQ:RZLT) Stock - MarketBeat
Rezolute (NASDAQ:RZLT) Insider Purchases 12,100 Shares - MarketBeat
Nevan Elam Increases Stake in Rezolute Inc with Recent Share Pur - GuruFocus
Elam Nevan C, Rezolute CEO, buys $50k in RZLT shares - Investing.com India
Rezolute’s CCO Karnawat buys $19,598 in shares - Investing.com India
Rezolute CFO Evans buys shares worth $79,577 - Investing.com
Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround - Finviz
Rezolute downgraded to neutral from outperform at Wedbush - MSN
Rezolute (RZLT): Reassessing Valuation After sunRIZE Phase 3 Failure and Growing Legal Scrutiny - simplywall.st
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Rezolute price target raised to $20 from $15 at Jefferies - MSN
H.C. Wainwright Maintains Rezolute(RZLT.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
HC Wainwright Decreases Earnings Estimates for Rezolute - MarketBeat
Rezolute (RZLT) Is Down 82.7% After Phase 3 sunRIZE Failure in Congenital Hyperinsulinism Trial - Yahoo Finance UK
Rezolute shares collapse after phase 3 trial fails to meet main goals - MSN
Rezolute (NASDAQ:RZLT) Downgraded by Citizens Jmp to Hold - MarketBeat
Rezolute’s phase 3 study in congenital hyperinsulinism did not meet endpoints - MSN
Investors Buy Large Volume of Rezolute Call Options (NASDAQ:RZLT) - MarketBeat
Guggenheim Issues Pessimistic Forecast for Rezolute (NASDAQ:RZLT) Stock Price - MarketBeat
Jefferies Raises Rezolute Price Target Amid Favorable Data Prospects - timothysykes.com
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute - TMX Newsfile
Wedbush downgrades Rezolute to neutral after congenital hyperinsulinism miss - MSN
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial FailureHagens Berman Investigating - The Malaysian Reserve
Rezolute (NASDAQ:RZLT) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Rezolute stock crashes after sole pipeline candidate fails Phase III - MSN
Rezolute (NASDAQ:RZLT) Reaches New 12-Month Low on Analyst Downgrade - MarketBeat
Guggenheim Maintains Rezolute (RZLT) Buy Recommendation - Nasdaq
Jefferies Raises Rezolute’s Price Target Amid Promising Drug Prospects - StocksToTrade
Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy - MSN
RZLT INVESTIGATION: Rezolute, Inc. Investors Should Contact Block & Leviton LLP To Potentially Recover Losses - TradingView — Track All Markets
Rezolute price target lowered to $4 from $20 at Maxim - MSN
Rezolute stock price target slashed by H.C. Wainwright after failed study - Investing.com Nigeria
Jefferies Lifts Rezolute’s Target amid New Data Anticipation - timothysykes.com
Craig-Hallum downgrades Rezolute stock to Hold on failed Phase III trial - Investing.com Australia
Rezolute Inc. trading resumes - MSN
Rezolute Inc trading halted, volatility trading pause - MSN
Rezolute decimated on Phase III miss for ersodetug - The Pharma Letter
Rezolute stock price target slashed by Guggenheim after trial failure - Investing.com Nigeria
RZLT Maintains Buy Rating despite Guggenheim's Lowered Price Tar - GuruFocus
Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts - ts2.tech
Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating - PR Newswire
Craig-Hallum Downgrades Rezolute to Hold From Buy, Adjusts PT to $2 From $18 - marketscreener.com
Buy Rating Maintained for XOMA Despite Rezolute Bio’s Trial Setback, Future Developments Anticipated - TipRanks
Rezolute (RZLT): HC Wainwright & Co. Significantly Lowers Price Target | RZLT Stock News - GuruFocus
HC Wainwright & Co. Maintains Rezolute (RZLT) Buy Recommendation - Nasdaq
Rezolute price target lowered to $5 from $14 at H.C. Wainwright - TipRanks
What analysts say about Rezolute Inc 6HV1 stockProtective Put Strategies & Rapid Portfolio Growth - earlytimes.in
Praxis tees up another approval filing; Geron turns to layoffs - Yahoo Finance
Rezolute, Inc. (NASDAQ:RZLT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Rezolute fails phase 3 for RZ358 as placebo response masks 10 mg/kg efficacyCHOSUNBIZ - Chosunbiz
Failed Trials And Missed Targets Send Shares Reeling - Finimize
Rezolute stock hits 52-week low at 1.21 USD despite strong annual gain - Investing.com Canada
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure - The AI Journal
Rezolute Inc. (RZLT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Rezolute stock price target cut to $5 from $17 at BTIG after trial failure - Investing.com Nigeria
Two Biotechs Crash, One Down 88%, On Failed Insulin Drug - Investor's Business Daily
Rezolute, Inc. (RZLT): The "sunRIZE" Post-Mortem & The Tumor Hyperinsulinism Pivot (NASDAQ:RZLT) - Seeking Alpha
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):